Anifrolumab

證據等級: L5

預測適應症: 0 個

Anifrolumab: From Systemic Lupus Erythematosus — No TxGNN Repurposing Predictions Available

One-Sentence Summary

Anifrolumab is a human monoclonal antibody targeting the type I interferon receptor (IFNAR1), approved in the US and EU for moderate-to-severe systemic lupus erythematosus (SLE). The current Evidence Pack contains no TxGNN-predicted indications — the prediction pipeline has not yet generated output for this candidate. This report documents available background data and identifies the critical gaps that must be resolved before a formal repurposing evaluation can proceed.

Quick Overview

Item	Content
Original Indication	Systemic Lupus Erythematosus (SLE), moderate-to-severe — based on global approval records
Predicted New Indication	Not available — TxGNN predictions not yet generated
TxGNN Prediction Score	Not available
Evidence Level	L5 — Prediction stage not yet reached
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Drug Background

Currently, detailed mechanism of action data is not available in this Evidence Pack (DG002). Based on known global pharmaceutical information, the following background is provided for reference.

Anifrolumab (brand name: SAPHNELO) is a fully human IgG1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1), thereby blocking the downstream signaling of all type I interferons — including IFN-α, IFN-β, and IFN-ω. Type I interferon overactivation is a well-established pathogenic driver in SLE, with elevated IFN gene expression signatures observed in approximately 60–80% of SLE patients.

Clinical efficacy was demonstrated in two Phase 3 trials (TULIP-1 and TULIP-2), leading to FDA approval in July 2021 and EMA approval in February 2022. The drug is not currently approved or marketed in Taiwan.

Because type I interferon dysregulation is mechanistically implicated in a broad spectrum of autoimmune and inflammatory conditions — including Sjögren's syndrome, inflammatory myopathies (dermatomyositis), systemic sclerosis, and ANCA-associated vasculitis — anifrolumab holds biological plausibility as a repurposing candidate across interferonopathies. However, no ranked TxGNN predictions are available in this Evidence Pack to formally evaluate this.

Clinical Trial Evidence

Currently no predicted indication is available — clinical trial evidence table cannot be generated. Once TxGNN predictions are produced, trials will be retrieved and tabulated for the top-ranked indication.

Literature Evidence

Currently no predicted indication is available — literature evidence table cannot be generated. Once TxGNN predictions are produced, relevant publications will be retrieved and tabulated.

Taiwan Market Information

No product authorizations are registered for Anifrolumab with the TFDA. The drug is not marketed in Taiwan. A total of 0 licenses were found in the regulatory query conducted on 2026-03-29.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package insert data (warnings and contraindications) was flagged as a Blocking data gap (DG001). Safety data could not be retrieved in this Evidence Pack cycle, preventing completion of the S1 safety triage. DDI query returned no results.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack contains no TxGNN-predicted indications, and a Blocking data gap in TFDA safety data prevents the S1 safety triage from being completed. No meaningful repurposing evaluation can proceed until both issues are resolved.

To proceed, the following is needed:

[Critical] Re-run TxGNN prediction pipeline for DB11976 (ANIFROLUMAB) to generate ranked new indication predictions
[Blocking] Download and parse TFDA package insert PDF to retrieve warnings and contraindications (DG001), enabling S1 safety triage
[High] Query DrugBank API to retrieve confirmed MOA data (DG002) for mechanism-linkage analysis
[Informational] Confirm whether a Taiwan licensing pathway is being considered, or whether the regulatory strategy relies on cross-referencing existing FDA/EMA approvals
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.